KCM
CLYM

Kynam Capital Management’s Climb Bio CLYM Stock Holding History

Kynam Capital Management’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.87M Sell
1,003,341
-25,000
-2% -$144K 0.42% 31
2025
Q4 		$4.11M Hold
1,028,341
– – 0.26% 31
2025
Q3 		$2.07M Hold
1,028,341
– – 0.15% 35
2025
Q2 		$1.28M Sell
1,028,341
-18,659
-2% -$23.2K 0.14% 31
2025
Q1 		$1.28M Buy
1,047,000
+500,000
+91% +$811K 0.11% 31
2024
Q4 		$985K Buy
+547,000
New +$1.98M 0.06% 30

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Kynam Capital Management's CLYM Position: Q1 2026 in Review

Kynam Capital Management reduced its Climb Bio (CLYM) stake by 2.4% in Q1 2026, selling an estimated $144K and leaving 1,003,341 shares worth $6.87M. The position accounts for 0.42% of the portfolio, ranked #31.

Kynam Capital Management first reported a position in CLYM in Q4 2024 and has held it in 6 quarters since. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • Kynam Capital Management held 1,003,341 shares of Climb Bio worth $6.87M as of Q1 2026.
  • Kynam Capital Management sold 25,000 Climb Bio shares in Q1 2026, an estimated $144K.
  • Climb Bio made up 0.42% of Kynam Capital Management's portfolio in Q1 2026, its #31 holding.
  • Kynam Capital Management first reported a position in Climb Bio in Q4 2024 and has held it in 6 quarters since.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on Kynam Capital Management's 13F filing for Q1 2026, filed 15 May 2026.